Tikva Allocell
PrivateLast Round
Series A
Jul 22, 2026
Est. Valuation
$40M
Total Funding Raised
$8M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Tikva Allocell is a biotechnology company that develops off-the-shelf allogeneic T-cell therapies for the treatment of solid tumors and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tikva Allocell Comparables
Compare Tikva Allocell with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| T-MAXIMUM Pharmaceutical | 82% | |
| BioSyngen | 77% | |
| TC BioPharm (Holdings) Plc | 77% | |
Tikva Allocell Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 22, 2026 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 236% to 474.
- Jul 22, 2026
$8M round raised
Tikva Allocell Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Tikva Allocell's valuation, stock price, and market status.